Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds

Kalpana Parikh, Ellen G. Duysen, Benjamin Snow, Neil S. Jensen, Veeraswamy Manne, Oksana Lockridge, Nageswararao Chilukuri

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Gene delivery using an adenoviral system has been effective in introducing therapeutic proteins in vitro and in vivo. This study tested the feasibility of using adenovirus to deliver clinically relevant amounts of butyrylcholinesterase (BChE), a proven bioscavenger of nerve agents. The adenovirus construct expressed full-length mouse BChE. Mice were injected with a single dose of adenovirus (1.5 × 10 10 infectious units) in the tail vein; plasma was collected through day 11 and assayed for BChE activity. Maximum activity, representing a 300- to 3400-fold increase over baseline, was found on day 4. Expression levels returned to baseline by day 10. Nondenaturing gel electrophoresis showed the recombinant BChE was a dimer that could be converted to tetramers by addition of polyproline. The toxic compounds chosen for protection studies were positively charged organophosphorus agents, echothiophate, and O-ethyl-S-2-N,N-diisopropylaminoethyl methylphosphonothiolate (VX). Mice containing elevated blood levels of BChE (300- to 3,000-fold over the control mice) were challenged with incremental doses of echothiophate or VX. Mice showed no signs of toxicity and were protected from up to 30X LD 50 dose of echothiophate and 5X LD 50 dose of VX. A good correlation was observed between tolerated echothiophate dose and plasma BChE levels at time of challenge. The absolute increases in levels of circulating BChE and the sustained nature of the response resulted in a very high enzyme concentration, deemed critical in acute toxicity (5X LD 50 or more) scenarios. These results suggest that gene-delivered BChE is a prophylactic and affords protection equivalent to that of a multimilligram injection of the same. U.S. Government work not protected by U.S. copyright.

Original languageEnglish (US)
Pages (from-to)92-101
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume337
Issue number1
DOIs
StatePublished - Apr 1 2011

Fingerprint

Chemical Warfare Agents
Organophosphorus Compounds
Butyrylcholinesterase
Genes
Adenoviridae
Nerve Agents
Poisons
Feasibility Studies
Electrophoresis
Tail
Veins
Gels
Injections

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. / Parikh, Kalpana; Duysen, Ellen G.; Snow, Benjamin; Jensen, Neil S.; Manne, Veeraswamy; Lockridge, Oksana; Chilukuri, Nageswararao.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 337, No. 1, 01.04.2011, p. 92-101.

Research output: Contribution to journalArticle

Parikh, Kalpana ; Duysen, Ellen G. ; Snow, Benjamin ; Jensen, Neil S. ; Manne, Veeraswamy ; Lockridge, Oksana ; Chilukuri, Nageswararao. / Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. In: Journal of Pharmacology and Experimental Therapeutics. 2011 ; Vol. 337, No. 1. pp. 92-101.
@article{94fbb1ffad4e47fb9f487643c1d09b41,
title = "Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds",
abstract = "Gene delivery using an adenoviral system has been effective in introducing therapeutic proteins in vitro and in vivo. This study tested the feasibility of using adenovirus to deliver clinically relevant amounts of butyrylcholinesterase (BChE), a proven bioscavenger of nerve agents. The adenovirus construct expressed full-length mouse BChE. Mice were injected with a single dose of adenovirus (1.5 × 10 10 infectious units) in the tail vein; plasma was collected through day 11 and assayed for BChE activity. Maximum activity, representing a 300- to 3400-fold increase over baseline, was found on day 4. Expression levels returned to baseline by day 10. Nondenaturing gel electrophoresis showed the recombinant BChE was a dimer that could be converted to tetramers by addition of polyproline. The toxic compounds chosen for protection studies were positively charged organophosphorus agents, echothiophate, and O-ethyl-S-2-N,N-diisopropylaminoethyl methylphosphonothiolate (VX). Mice containing elevated blood levels of BChE (300- to 3,000-fold over the control mice) were challenged with incremental doses of echothiophate or VX. Mice showed no signs of toxicity and were protected from up to 30X LD 50 dose of echothiophate and 5X LD 50 dose of VX. A good correlation was observed between tolerated echothiophate dose and plasma BChE levels at time of challenge. The absolute increases in levels of circulating BChE and the sustained nature of the response resulted in a very high enzyme concentration, deemed critical in acute toxicity (5X LD 50 or more) scenarios. These results suggest that gene-delivered BChE is a prophylactic and affords protection equivalent to that of a multimilligram injection of the same. U.S. Government work not protected by U.S. copyright.",
author = "Kalpana Parikh and Duysen, {Ellen G.} and Benjamin Snow and Jensen, {Neil S.} and Veeraswamy Manne and Oksana Lockridge and Nageswararao Chilukuri",
year = "2011",
month = "4",
day = "1",
doi = "10.1124/jpet.110.175646",
language = "English (US)",
volume = "337",
pages = "92--101",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds

AU - Parikh, Kalpana

AU - Duysen, Ellen G.

AU - Snow, Benjamin

AU - Jensen, Neil S.

AU - Manne, Veeraswamy

AU - Lockridge, Oksana

AU - Chilukuri, Nageswararao

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Gene delivery using an adenoviral system has been effective in introducing therapeutic proteins in vitro and in vivo. This study tested the feasibility of using adenovirus to deliver clinically relevant amounts of butyrylcholinesterase (BChE), a proven bioscavenger of nerve agents. The adenovirus construct expressed full-length mouse BChE. Mice were injected with a single dose of adenovirus (1.5 × 10 10 infectious units) in the tail vein; plasma was collected through day 11 and assayed for BChE activity. Maximum activity, representing a 300- to 3400-fold increase over baseline, was found on day 4. Expression levels returned to baseline by day 10. Nondenaturing gel electrophoresis showed the recombinant BChE was a dimer that could be converted to tetramers by addition of polyproline. The toxic compounds chosen for protection studies were positively charged organophosphorus agents, echothiophate, and O-ethyl-S-2-N,N-diisopropylaminoethyl methylphosphonothiolate (VX). Mice containing elevated blood levels of BChE (300- to 3,000-fold over the control mice) were challenged with incremental doses of echothiophate or VX. Mice showed no signs of toxicity and were protected from up to 30X LD 50 dose of echothiophate and 5X LD 50 dose of VX. A good correlation was observed between tolerated echothiophate dose and plasma BChE levels at time of challenge. The absolute increases in levels of circulating BChE and the sustained nature of the response resulted in a very high enzyme concentration, deemed critical in acute toxicity (5X LD 50 or more) scenarios. These results suggest that gene-delivered BChE is a prophylactic and affords protection equivalent to that of a multimilligram injection of the same. U.S. Government work not protected by U.S. copyright.

AB - Gene delivery using an adenoviral system has been effective in introducing therapeutic proteins in vitro and in vivo. This study tested the feasibility of using adenovirus to deliver clinically relevant amounts of butyrylcholinesterase (BChE), a proven bioscavenger of nerve agents. The adenovirus construct expressed full-length mouse BChE. Mice were injected with a single dose of adenovirus (1.5 × 10 10 infectious units) in the tail vein; plasma was collected through day 11 and assayed for BChE activity. Maximum activity, representing a 300- to 3400-fold increase over baseline, was found on day 4. Expression levels returned to baseline by day 10. Nondenaturing gel electrophoresis showed the recombinant BChE was a dimer that could be converted to tetramers by addition of polyproline. The toxic compounds chosen for protection studies were positively charged organophosphorus agents, echothiophate, and O-ethyl-S-2-N,N-diisopropylaminoethyl methylphosphonothiolate (VX). Mice containing elevated blood levels of BChE (300- to 3,000-fold over the control mice) were challenged with incremental doses of echothiophate or VX. Mice showed no signs of toxicity and were protected from up to 30X LD 50 dose of echothiophate and 5X LD 50 dose of VX. A good correlation was observed between tolerated echothiophate dose and plasma BChE levels at time of challenge. The absolute increases in levels of circulating BChE and the sustained nature of the response resulted in a very high enzyme concentration, deemed critical in acute toxicity (5X LD 50 or more) scenarios. These results suggest that gene-delivered BChE is a prophylactic and affords protection equivalent to that of a multimilligram injection of the same. U.S. Government work not protected by U.S. copyright.

UR - http://www.scopus.com/inward/record.url?scp=79953004602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953004602&partnerID=8YFLogxK

U2 - 10.1124/jpet.110.175646

DO - 10.1124/jpet.110.175646

M3 - Article

C2 - 21205915

AN - SCOPUS:79953004602

VL - 337

SP - 92

EP - 101

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -